AR041816A1 - Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo - Google Patents
Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararloInfo
- Publication number
- AR041816A1 AR041816A1 ARP030103852A ARP030103852A AR041816A1 AR 041816 A1 AR041816 A1 AR 041816A1 AR P030103852 A ARP030103852 A AR P030103852A AR P030103852 A ARP030103852 A AR P030103852A AR 041816 A1 AR041816 A1 AR 041816A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- hydrogen
- heteroarylalkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000001072 heteroaryl group Chemical group 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 8
- 150000002431 hydrogen Chemical class 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- -1 acyl-pyrrolidine compound Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000004122 cyclic group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 abstract 2
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 abstract 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- RXKSUQZUBGLJQC-UHFFFAOYSA-N diethyl 4-(1-hydroxyethyl)-1-(2-nitrobenzoyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CC(C(C)O)CN1C(=O)C1=CC=CC=C1[N+]([O-])=O RXKSUQZUBGLJQC-UHFFFAOYSA-N 0.000 abstract 2
- LHTLMSMNROQTDU-UHFFFAOYSA-N diethyl 4-ethenyl-1-(2-nitrobenzoyl)pyrrolidine-2,2-dicarboxylate Chemical compound CCOC(=O)C1(C(=O)OCC)CC(C=C)CN1C(=O)C1=CC=CC=C1[N+]([O-])=O LHTLMSMNROQTDU-UHFFFAOYSA-N 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Un compuesto de acil-pirrolidina que tiene la fórmula (1), en la que: A representa hidroxi; D representa arilo o heteroarilo; E representa hidrógeno, alquilo C1-6, arilo, heteroarilo o heterociclilo; G representa hidrógeno o alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, OR1, SR1, C(O)NR2R3, CO2H, C(O)R4, CO2R4, NR2R3, NHC(O)R4, NHCO2R4, NHC(O)NR5R6, SO2NR5R6, SO2R4, nitro, ciano, arilo, heteroarilo y heterociclilo; R1 representa hidrógeno, alquilo 1-6, arilalquilo, o heteroarilalquilo; R2 y R3 se seleccionan independientemente de hidrógeno, alquilo C1-6, arilo y heteroarilo; o R2 y R3 junto con el átomo de nitrógeno al que están unidos forman un grupo cíclico saturado de 5 ó 6 miembros; R4 se selecciona del grupo que consta de alquilo C1-6, arilo, heteroarilo, arilalquilo, y heteroarilalquilo; R5 y R6 se seleccionan independientemente del grupo que consta de hidrógeno, alquilo C1-6, arilo, heteroarilo, arilalquilo, y heteroarilalquilo; o R5 y R6 junto con el átomo de nitrógeno al que están unidos forman un grupo cíclico saturado de 5 ó 6 miembros; y J representa alquilo C1-6, heterociclilalquilo, arilalquilo o heteroarilalquilo; con la condición de que i) E y G no sean ambos hidrógeno; y ii) el compuesto sea distinto de éster dietílico del ácido 4-etenil-1-(2-nitrobenzoil)-2,2-pirrolidinadicarboxílico; éster dietílico del ácido 1-(2-aminobenzoil)-4-(1-hidroxietil)-2,2-pirrodinadicarboxílico; éster dietílico del ácido 4-(1-hidroxietil)-1-(2-nitrobenzoil)-2,2-pirrolidinadicarboxílico; y sus sales, solvatos y ésteres; con la condición de que cuando A esté esterificado para formar -OR donde R se selecciona de alquilo de cadena lineal o ramificada, aralquilo, ariloxialquilo, o arilo, entonces, R es distinto de terc-butilo. Estos compuestos son agentes antivíricos efectivos. Un procedimiento para su preparación, composiciones farmacéuticas que los comprenden, y su uso para preparar medicamentos para usarlos en el tratamiento del VHC. Reivindicación 1: Un compuesto de acil-pirrolidina caracterizado porque tiene la fórmula (1), en la que: A representa hidroxi; D representa arilo o heteroarilo; E representa hidrógeno, alquilo C1-6, arilo, heteroarilo o heterociclilo; G representa hidrógeno o alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes seleccionados de halógeno, OR1, SR1, C(O)NR2R3, CO2H, C(O)R4, CO2R4, NR2R3, NHC(O)R4, NHCO2R4, NHC(O)NR5R6, SO2NR5R6, SO2R4, nitro, ciano, arilo, heteroarilo y heterociclilo; R1 representa hidrógeno, alquilo 1-6, arilalquilo, o heteroarilalquilo; R2 y R3 se seleccionan independientemente de hidrógeno, alquilo C1-6, arilo y heteroarilo; o R2 y R3 junto con el átomo de nitrógeno al que están unidos forman un grupo cíclico saturado de 5 ó 6 miembros; R4 se selecciona del grupo que consta de alquilo C1-6, arilo, heteroarilo, arilalquilo, y heteroarilalquilo; R5 y R6 se seleccionan independientemente del grupo que consta de hidrógeno, alquilo C1-6, arilo, heteroarilo, arilalquilo, y heteroarilalquilo; o R5 y R6 junto con el átomo de nitrógeno al que están unidos forman un grupo cíclico saturado de 5 ó 6 miembros; y J representa alquilo C1-6, heterociclilalquilo, arilalquilo o heteroarilalquilo; con la condición de que i) E y G no sean ambos hidrógeno; y ii) el compuesto sea distinto de éster dietílico del ácido 4-etenil-1-(2-nitrobenzoil)-2,2-pirrolidinadicarboxílico; éster dietílico del ácido 1-(2-aminobenzoil)-4-(1-hidroxietil)-2,2-pirrodinadicarboxílico; éster dietílico del ácido 4-(1-hidroxietil)-1-(2-nitrobenzoil)-2,2-pirrolidinadicarboxílico; y sus sales, solvatos y ésteres; con la condición de que cuando A esté esterificado para formar -OR donde R se selecciona de alquilo de cadena lineal o ramificada, aralquilo, ariloxialquilo, o arilo, entonces R es distinto de terc-butilo. Reivindicación 22: Un procedimiento para preparar un compuesto de fórmula (1) como se ha definido en la reivindicación 13, caracterizado porque comprende el tratamiento de un compuesto de fórmula (1), en la que A es alcoxi, y D, E, G y J son como se ha definido para la fórmula (1), con un ácido.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0224774A GB0224774D0 (en) | 2002-10-24 | 2002-10-24 | Compounds |
| GB0229470A GB0229470D0 (en) | 2002-12-18 | 2002-12-18 | Compounds |
| GB0317141A GB0317141D0 (en) | 2003-07-22 | 2003-07-22 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041816A1 true AR041816A1 (es) | 2005-06-01 |
Family
ID=32180212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103852A AR041816A1 (es) | 2002-10-24 | 2003-10-22 | Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7304087B2 (es) |
| EP (1) | EP1554274B1 (es) |
| JP (1) | JP2006506455A (es) |
| KR (1) | KR20050057670A (es) |
| AR (1) | AR041816A1 (es) |
| AT (1) | ATE418554T1 (es) |
| AU (1) | AU2003276172A1 (es) |
| BR (1) | BR0315417A (es) |
| CA (1) | CA2503471A1 (es) |
| CO (1) | CO5550450A2 (es) |
| DE (1) | DE60325498D1 (es) |
| IS (1) | IS7851A (es) |
| MA (1) | MA27524A1 (es) |
| MX (1) | MXPA05004435A (es) |
| NO (1) | NO20052472L (es) |
| PL (1) | PL376454A1 (es) |
| TW (1) | TW200418848A (es) |
| WO (1) | WO2004037818A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304494D0 (en) * | 2003-02-27 | 2003-04-02 | Glaxo Group Ltd | Compounds |
| GB0408995D0 (en) * | 2004-04-22 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| GB0423673D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| GB0423672D0 (en) * | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| EP1814861A1 (en) | 2004-10-29 | 2007-08-08 | Schering Corporation | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents |
| GB0519486D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519488D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519485D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| GB0519478D0 (en) * | 2005-09-23 | 2005-11-02 | Glaxo Group Ltd | Compounds |
| EP2144604B1 (en) | 2007-02-28 | 2011-09-21 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of chronic viral hepatitis C using RO 113-0830 |
| EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| EP2272832A4 (en) | 2008-04-28 | 2011-09-07 | Asahi Kasei Pharma Corp | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF |
| CA2733750C (en) | 2008-08-11 | 2016-10-11 | Glaxosmithkline Llc | Novel adenine derivatives |
| AU2009281195A1 (en) | 2008-08-11 | 2010-02-18 | Glaxosmithkline Llc | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| EP2534148A1 (en) | 2010-02-10 | 2012-12-19 | GlaxoSmithKline LLC | Purine derivatives and their pharmaceutical uses |
| SI2534149T1 (sl) | 2010-02-10 | 2015-02-27 | Glaxosmithkline Llc Corporation Service Company | 6-amino-2-((1S)-1-metilbutil)oksi)-9-(5-(1-pipridinil)pentil)-7,9- dihidro-8H purin-8-on maleat |
| WO2013134012A1 (en) | 2012-03-06 | 2013-09-12 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| CA2938476A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
| BR112017009648A2 (pt) | 2014-11-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto. |
| HK1250032A1 (zh) | 2015-12-03 | 2018-11-23 | Glaxosmithkline Intellectual Property Development Limited | 作为sting调节剂的环状嘌呤二核苷酸 |
| US10975287B2 (en) | 2016-04-07 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| AU2017247798C1 (en) | 2016-04-07 | 2020-08-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 |
| EP3969438A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| AU2020409429A1 (en) | 2019-12-18 | 2022-06-16 | Ctxt Pty Ltd | Compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2218716A1 (en) | 1995-04-21 | 1996-10-24 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
| WO1999029705A2 (en) | 1997-12-08 | 1999-06-17 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| US6537211B1 (en) | 1998-01-26 | 2003-03-25 | Massachusetts Institute Of Technology | Flourescence imaging endoscope |
| IL138601A0 (en) * | 1998-04-23 | 2001-10-31 | Abbott Lab | Pyrrolidines as inhibitors of neuraminidases |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1118287B1 (de) * | 2000-01-21 | 2004-11-24 | Alois Ing. Sampl | Steckbares Regalsystem |
| US6713502B2 (en) * | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
| US6890938B2 (en) | 2000-11-20 | 2005-05-10 | Scios, Inc. | Indole-type inhibitors of p38 kinase |
| EP1438308A1 (en) | 2001-10-26 | 2004-07-21 | PHARMACIA & UPJOHN COMPANY | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
| JP2005511572A (ja) | 2001-11-02 | 2005-04-28 | グラクソ グループ リミテッド | Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体 |
| US20060167702A1 (en) | 2002-10-28 | 2006-07-27 | Pierre-Paul Jodoin | Method of preventing theft to vehicles using intensive marking |
-
2003
- 2003-10-22 WO PCT/EP2003/011813 patent/WO2004037818A1/en not_active Ceased
- 2003-10-22 MX MXPA05004435A patent/MXPA05004435A/es unknown
- 2003-10-22 BR BR0315417-3A patent/BR0315417A/pt not_active IP Right Cessation
- 2003-10-22 CA CA002503471A patent/CA2503471A1/en not_active Abandoned
- 2003-10-22 DE DE60325498T patent/DE60325498D1/de not_active Expired - Fee Related
- 2003-10-22 US US10/531,884 patent/US7304087B2/en not_active Expired - Fee Related
- 2003-10-22 PL PL03376454A patent/PL376454A1/xx not_active Application Discontinuation
- 2003-10-22 AT AT03809322T patent/ATE418554T1/de not_active IP Right Cessation
- 2003-10-22 AU AU2003276172A patent/AU2003276172A1/en not_active Abandoned
- 2003-10-22 JP JP2005501534A patent/JP2006506455A/ja not_active Withdrawn
- 2003-10-22 KR KR1020057006957A patent/KR20050057670A/ko not_active Withdrawn
- 2003-10-22 AR ARP030103852A patent/AR041816A1/es not_active Application Discontinuation
- 2003-10-22 TW TW092129213A patent/TW200418848A/zh unknown
- 2003-10-22 EP EP03809322A patent/EP1554274B1/en not_active Expired - Lifetime
-
2005
- 2005-04-25 CO CO05038997A patent/CO5550450A2/es not_active Application Discontinuation
- 2005-05-06 MA MA28263A patent/MA27524A1/fr unknown
- 2005-05-19 IS IS7851A patent/IS7851A/is unknown
- 2005-05-23 NO NO20052472A patent/NO20052472L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004037818A1 (en) | 2004-05-06 |
| CA2503471A1 (en) | 2004-05-06 |
| BR0315417A (pt) | 2005-08-16 |
| ATE418554T1 (de) | 2009-01-15 |
| PL376454A1 (en) | 2005-12-27 |
| KR20050057670A (ko) | 2005-06-16 |
| EP1554274A1 (en) | 2005-07-20 |
| US20060258720A1 (en) | 2006-11-16 |
| IS7851A (is) | 2005-05-19 |
| EP1554274B1 (en) | 2008-12-24 |
| NO20052472L (no) | 2005-05-23 |
| AU2003276172A1 (en) | 2004-05-13 |
| CO5550450A2 (es) | 2005-08-31 |
| TW200418848A (en) | 2004-10-01 |
| JP2006506455A (ja) | 2006-02-23 |
| DE60325498D1 (de) | 2009-02-05 |
| US7304087B2 (en) | 2007-12-04 |
| MA27524A1 (fr) | 2005-09-01 |
| MXPA05004435A (es) | 2005-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041816A1 (es) | Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| CY1108445T1 (el) | Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| ATE478044T1 (de) | Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c | |
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| NO20065929L (no) | Sykliske amidderivater, deres fremstilling og anvendelse | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| ATE73797T1 (de) | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel. | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| EA201000413A1 (ru) | Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида | |
| EA200970171A1 (ru) | Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| HRP20040690B1 (en) | Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals | |
| CY1108529T1 (el) | Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν | |
| NO20052976L (no) | Fosfodiesterase-4-inhibitorer. | |
| EA200500268A1 (ru) | Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии | |
| CY1106343T1 (el) | Παραγωγα νικοτιναμιδιου χρησιμα σαν pde4 αναστολεις | |
| HRP20090474T1 (hr) | Postupak i intermedijeri za sintezu kaspofungina | |
| AR042362A1 (es) | Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen | |
| EA200970364A1 (ru) | Новые производные имидазолонов в качестве лекарственных средств, способ их получения, фармацевтические композиции и применение в качестве ингибиторов протеинкиназ, в частности, cdc7 | |
| NO20076000L (no) | Aminosyrederivater | |
| PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
| ATE543803T1 (de) | 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren | |
| EA200900478A1 (ru) | Жидкая пестицидная композиция, содержащая n-фенилсемикарбазоновые пестицидные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |